U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
Več na: https://www.nytimes.com/2025/04/16/health/obesity-drugs-fda-compounding-wegovy-zepbound.html